TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32350792

Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs) such as apixaban and edoxaban
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 40
Study: 35848873

Group type: EXPERIMENTAL
Intervention: miR-1343-5p
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: miR-6087
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Serum levels of identified miRNAs
Number of subjects: 126
Study: 32901243

Group type: EXPERIMENTAL
Intervention: Desensitizing-containing hydrogen peroxide gel (5% potassium nitrate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desensitizing-free hydrogen peroxide gel (35%)
Number of subjects: 60
Study: 33842864

Group type: EXPERIMENTAL
Intervention: Rapid-test-guided treatment for ASB
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual hospital-care (Control)
Number of subjects: 240
Study: 32445190

Group type: EXPERIMENTAL
Intervention: 0.5 mg Δ9-THC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1 mg Δ9-THC
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 35855512

Group type: EXPERIMENTAL
Intervention: 30-second chair stand test (30CST)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lateral step-up test (LSUT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Modified lateral step-up test (MLSUT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 5 times sit to stand (5×STS)
Number of subjects: 81
Study: 33168942

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC) - 3 × 5 min ischemia/reperfusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mock IPC
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Remote IPC
Number of subjects: 22

Group type: COMPARATOR
Intervention: Endothelial ischemia-reperfusion (I/R) injury
Number of subjects: 22
Study: 32004693

Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Inactivated poliovirus vaccine
Number of subjects: 200
Study: 35676445

Group type: EXPERIMENTAL
Intervention: Multimodal deep learning architecture for therapy personalization
Number of subjects: 7764

Group type: COMPARATOR
Intervention: NCCN risk groups (control)
Number of subjects: 7764
Study: 33601698

Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Interoceptive Awareness (MAIA) - body trusting
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Interoceptive Awareness (MAIA) - body listening
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Interoceptive Awareness (MAIA) - noticing
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Interoceptive Awareness (MAIA) - emotional awareness
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Multidimensional Assessment of Interoceptive Awareness (MAIA) - self-regulation
Number of subjects: 281
Study: 35500415

Group type: EXPERIMENTAL
Intervention: Narrative pedagogy of geriatric care course for 18 weeks, 2 hours per week
Number of subjects: 87

Group type: COMPARATOR
Intervention: General lectures (Control group)
Number of subjects: 87
Study: 34184426

Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IMT + AET
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IMT
Number of subjects: 42

Group type: COMPARATOR
Intervention: NT
Number of subjects: 42
Study: 32033913

Group type: EXPERIMENTAL
Intervention: Random Forest + Classifier Attribute Evaluation (RF+CLAE)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Random Forest + One Rule Attribute Evaluation (RF+ORAE)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Random Committee + One Rule Attribute Evaluation (RC+ORAE)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Random Forest + Principal Components Analysis (RF+PRCA)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Logit-Boost + Principal Components Analysis (LB+PRCA)
Number of subjects: 147
Study: 35704556

Group type: EXPERIMENTAL
Intervention: Voluntary medical male circumcision (VMMC)
Number of subjects: 6416

Group type: EXPERIMENTAL
Intervention: Referral from HIV testing services
Number of subjects: 6416

Group type: EXPERIMENTAL
Intervention: Referral acceptance
Number of subjects: 6416

Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 6416

Group type: EXPERIMENTAL
Intervention: Reasons for not being circumcised
Number of subjects: 6416
Study: 33784987

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV) with a tidal volume (Vt) of 7 ml kg−1 ideal body weight (IBW), 10 cmH2O positive end-expiratory pressure (PEEP) combined with regular recruitment maneuvers (RMs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional ventilation (CV) with a Vt of 10 ml kg−1 IBW, 0 cmH2O in PEEP and no RMs
Number of subjects: 62
Study: 33128399

Group type: EXPERIMENTAL
Intervention: Modified Papilla Preservation Technique (mPPT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination with Autogenous Bone Grafts (AG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of mPPT and AG
Number of subjects: 44

Group type: COMPARATOR
Intervention: rhFGF-2 therapy
Number of subjects: 44
Study: 35980309

Group type: EXPERIMENTAL
Intervention: CDC HEADS UP handouts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education as usual
Number of subjects: 0
Study: 32827404

Group type: EXPERIMENTAL
Intervention: Brief Guided Imagery (BGI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study: 35594703

Group type: EXPERIMENTAL
Intervention: Nintedanib with green tea extract (GTE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nintedanib alone
Number of subjects: 26
Study: 32562575

Group type: EXPERIMENTAL
Intervention: Emollient with basic pH 8.5
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Emollient with pH 5.5
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline S. aureus frequency
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls (HE)
Number of subjects: 12
Study: 33952529

Group type: EXPERIMENTAL
Intervention: HepCATT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32363638

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 100 mg/day orally for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydroxyzine (HYDZ) 25 mg/day orally for 6 weeks
Number of subjects: 32
Study: 36362612

Group type: EXPERIMENTAL
Intervention: Perineural catheter with ropivacaine infiltration (ROPI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Systemic analgesia (CONTROL)
Number of subjects: 56
Study: 32526490

Group type: EXPERIMENTAL
Intervention: Alcoholic beer (BAC = 0.06)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Alcoholic beer (BAC = 0.03)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-alcoholic beer (placebo-control group)
Number of subjects: 125
Study: 34120463

Group type: EXPERIMENTAL
Intervention: Cream with lipid nanoparticles and vitamin E (Group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cream without nanoparticles nor vitamin E (Group B)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cream with nanoparticles without vitamin E (Group C)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 108
Study: 33541495

Group type: EXPERIMENTAL
Intervention: rhTPO 15,000 U, once daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 100
Study: 34407729

Group type: EXPERIMENTAL
Intervention: Kojic acid combined with fractional Er:YAG laser
Number of subjects: 25

Group type: COMPARATOR
Intervention: Kojic acid alone
Number of subjects: 25
Study: 32337693

Group type: EXPERIMENTAL
Intervention: Sheng Xue Ning (SXN) tablets
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ferrous succinate (FS) tablets
Number of subjects: 94
Study: 34397819

Group type: EXPERIMENTAL
Intervention: Group I (chronic periodontitis with smoking and stress)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Group II (chronic periodontitis without smoking and stress)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Group III (control group, healthy subjects)
Number of subjects: 600
Study: 33050179

Group type: EXPERIMENTAL
Intervention: Physical Therapeutic Exercise Programme (PTE) added to Family Caregiver Care Programme (FCCP)
Number of subjects: 68
Study: 36026657

Group type: EXPERIMENTAL
Intervention: Dynamic Resistance Exercise (DRE)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined Resistance Exercise (CRE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Isometric Handgrip (IH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (CO) - seated resting
Number of subjects: 70
Study: 33899450

Group type: EXPERIMENTAL
Intervention: ALMAG + magnetic therapy device
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo devices
Number of subjects: 70
Study: 36088457

Group type: EXPERIMENTAL
Intervention: PROGROUP (a novel group-based behavioural intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32484754

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) treatments (arm 1)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: SOC plus stereotactic ablative radiotherapy (SABR) (arm 2)
Number of subjects: 99
Study: 34479861

Group type: EXPERIMENTAL
Intervention: IPTp with sulfadoxine‐pyrimethamine (SP) and azithromycin (AZI)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Control (twice with SP)
Number of subjects: 1320
Study: 34996111

Group type: EXPERIMENTAL
Intervention: Immersive VR (IVR) using Oculus Go Standalone headset with games (Temple Run or Roller Coaster)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-immersive VR (NIVR) watching cartoon movies
Number of subjects: 200
Study: 36205268

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diagnostic strategies (Control)
Number of subjects: 0
Study: 34127127

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 32591246

Group type: EXPERIMENTAL
Intervention: SOC + prostate RT
Number of subjects: 660

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 660
Study: 35780104

Group type: EXPERIMENTAL
Intervention: Combined physio-hemsball training for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 34611000

Group type: EXPERIMENTAL
Intervention: iPACK block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Periarticular local infiltration analgesia (LIA)
Number of subjects: 80
Study: 32579813

Group type: EXPERIMENTAL
Intervention: Hydroxyurea with dose escalation (approximately 30 mg per kilogram per day)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Hydroxyurea at a fixed dose (approximately 20 mg per kilogram of body weight per day)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Dose escalation group
Number of subjects: 187
Study: 615918278

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2.0 mg every 8 weeks after 3 initial monthly doses (2q8)
Number of subjects: 799
Study: 35114057

Group type: EXPERIMENTAL
Intervention: mesorectal long course chemoradiation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: mesorectal short course radiotherapy with selective transanal microsurgery
Number of subjects: 500

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: acute treatment-related toxicity
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: non-operative management
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: non-regrowth pelvic tumour control at 36 months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: non-regrowth disease free survival at 36 months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: overall survival at 60 months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: patient reported toxicity
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: health related QOL
Number of subjects: 500
Study: 33285371

Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES) for 7 consecutive days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 47
Study: 33914945

Group type: EXPERIMENTAL
Intervention: Active transcranial Direct Current Stimulation (tDCS) to the ventrolateral prefrontal cortex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 32744358

Group type: EXPERIMENTAL
Intervention: metformin + PEX168 100 μg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: metformin + PEX168 200 μg
Number of subjects: 44

Group type: COMPARATOR
Intervention: metformin + placebo
Number of subjects: 44
Study: 35543263

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Rectus Sheath Catheter Analgesia (RSCA)
Number of subjects: 131
Study: 32060740

Group type: EXPERIMENTAL
Intervention: 2-week heavy-load strength-training program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early training sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Later training sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-week strength-training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 35272403

Group type: EXPERIMENTAL
Intervention: High-frequency acupuncture (5 times weekly for weeks 1-4, 3 times weekly for weeks 5-8)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-frequency acupuncture (3 times weekly for weeks 1-4, 2 times weekly for weeks 5-8)
Number of subjects: 120

Group type: COMPARATOR
Intervention: High nicotine metabolite rate (NMR) patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low nicotine metabolite rate (NMR) patients
Number of subjects: 120
Study: 34077434

Group type: EXPERIMENTAL
Intervention: Dilute apple cider vinegar (0.5% acetic acid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study: 35668567

Group type: EXPERIMENTAL
Intervention: Norepinephrine plus ulinastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Norepinephrine (control group)
Number of subjects: 100
Study: 33860924

Group type: EXPERIMENTAL
Intervention: Vericiguat plus guideline-directed medical therapy (GDMT)
Number of subjects: 20510

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) plus placebo
Number of subjects: 20510
Study: 35834620

Group type: EXPERIMENTAL
Intervention: Home-mailed delivery of a vaginal self-sampling kit
Number of subjects: 3612

Group type: COMPARATOR
Intervention: General practitioner (GP) delivery of a vaginal self-sampling kit
Number of subjects: 3612
Study: 33091174

Group type: EXPERIMENTAL
Intervention: High fermentable fiber intake (13 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low fermentable fiber intake (≤ 2 g)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hypothetical coating dissolution profiles
Number of subjects: 18
Study: 36691173

Group type: EXPERIMENTAL
Intervention: Two doses of 11.4 mg betamethasone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 88
Study: 35995785

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 7000 mg
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 317

Group type: COMPARATOR
Intervention: Blinded placebo
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Number of subjects: 317
Study: 33992566

Group type: EXPERIMENTAL
Intervention: Knowledge about prognosis generated from electronic health record and presented to providers.
Number of subjects: 3124
Study: 32826015

Group type: EXPERIMENTAL
Intervention: IASTM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vibration Massage
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Light Hand Massage
Number of subjects: 16
Study: 32228099

Group type: EXPERIMENTAL
Intervention: Polypropylene
Number of subjects: 213

Group type: COMPARATOR
Intervention: Polyglactin 910
Number of subjects: 213
Study: 34627611

Group type: EXPERIMENTAL
Intervention: DMUC4064A (5.2 mg/kg RP2D)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DMUC4064A (≥3.2 mg/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DMUC4064A
Number of subjects: 65
Study: 32174632

Group type: EXPERIMENTAL
Intervention: Bach flower therapy (BFT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Music therapy (MT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 35508656

Group type: EXPERIMENTAL
Intervention: AMG319
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of PI3Kδi
Number of subjects: 21
Study: 33120207

Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 274

Group type: COMPARATOR
Intervention: Discrimination and stigma trajectories
Number of subjects: 274

Group type: COMPARATOR
Intervention: Housing stability
Number of subjects: 274

Group type: COMPARATOR
Intervention: Recovery
Number of subjects: 274

Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 274

Group type: COMPARATOR
Intervention: Community functioning
Number of subjects: 274
Study: 34558835

Group type: EXPERIMENTAL
Intervention: Ipragliflozin (50 mg/day for 72 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no SGLT2is, pioglitazone, GLP-1 analogs, or insulin)
Number of subjects: 51
Study: 33610212

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36241463

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg plus ezetimibe 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pitavastatin 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg plus ezetimibe 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pitavastatin 4 mg
Number of subjects: 0
Study: 33027558

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Depressive status (ever depressed for a whole week)
Number of subjects: 44
Study: 32408795

Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Staff-led activity group (usual care)
Number of subjects: 12
Study: 33057705

Group type: COMPARATOR
Intervention: no-PADN
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: instant-PADN
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1M-PADN
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2M-PADN
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3M-PADN
Number of subjects: 45
Study: 35392963

Group type: EXPERIMENTAL
Intervention: Probenecid (1 g orally twice per day for 180 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34115990

Group type: EXPERIMENTAL
Intervention: Dose Optimization for Stone Evaluation intervention (customized CME modules, personalized consultation, and protocol recommendations for RDCT)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Intervened-on group
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study: 33415869

Group type: EXPERIMENTAL
Intervention: Huayu Tongluo moxibustion applied at Baihui (GV 20), Dazhui (GV 14), Shenting (GV 24), once every 2 days for 4 weeks, total of 3 courses
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional hypoglycemic intervention
Number of subjects: 47
Study: 33860116

Group type: EXPERIMENTAL
Intervention: Resmetirom (80 or 100 mg orally per day)
Number of subjects: 31
Study: 32428586

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Online Program (OP)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Combined Intervention (CI)
Number of subjects: 840
Study: 36217872

Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg/284 mg (free acid) administered at days 1, 90, 270 and 450
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 33331857

Group type: EXPERIMENTAL
Intervention: Integrated palliative and oncology care (IPC)
Number of subjects: 160
Study: 32703194

Group type: EXPERIMENTAL
Intervention: Oral morphine drops (5 mg, four daily doses for 1 week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35384021

Group type: EXPERIMENTAL
Intervention: Low-dose rituximab (500 mg, 2 weeks apart)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rheumatoid arthritis protocol (1000 mg given as two doses, 2 weeks apart)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups received short-term oral corticosteroids
Number of subjects: 23
Study: 33491116

Group type: EXPERIMENTAL
Intervention: Process-based incentive arm
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Outcome-based incentive arm
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combined incentive arms
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Process-based incentives
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care plus (UC +)
Number of subjects: 240
Study: 32268815

Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and low-dose dexamethasone (PVd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and low-dose dexamethasone (Vd)
Number of subjects: 0
Study: 34459271

Group type: EXPERIMENTAL
Intervention: Education (brief psychoeducation and treatment resources)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Education+Motivation (Education plus treatment seeking-focused motivational content)
Number of subjects: 267
Study: 34662275

Group type: EXPERIMENTAL
Intervention: Anecdote alone
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Anecdote combined with clinical trial evidence
Number of subjects: 222

Group type: COMPARATOR
Intervention: Clinical trial evidence alone
Number of subjects: 222
Study: 32078787

Group type: EXPERIMENTAL
Intervention: AkP05 nutraceutical combination
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 69
Study: 35314453

Group type: EXPERIMENTAL
Intervention: Modified speed CPET
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fixed speed CPET
Number of subjects: 22